Catalent Acquires Delphi Genetics to Add Plasmid DNA Capabilities
February 23, 2021
Catalent has agreed to acquire 100% of Delphi Genetics, a Belgium-based plasmid DNA (pDNA) CDMO, and will integrate Delphi's pDNA development and cGMP manufacturing capabilities into its Cell & Gene Therapy business. The deal also supports Catalent's launch of pDNA services at its Rockville, Maryland facility, expanding integrated pDNA supply across Europe and the U.S.
- Buyers
- Catalent, Inc.
- Targets
- Delphi Genetics S.A.
- Industry
- Biotechnology
- Location
- Hainaut, Belgium
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Catalent Acquires Paragon Bioservices for $1.2 Billion
May 20, 2019
Biotechnology
Catalent, Inc. completed the $1.2 billion acquisition of Paragon Bioservices, Inc., a viral vector development and manufacturing partner for gene therapies, expanding Catalent’s biologics and gene therapy capabilities. Paragon’s Baltimore-area facilities and ~380 employees will join Catalent’s global biologics platform, while Catalent secured financing including incremental term loans and a convertible preferred issuance to Leonard Green & Partners to support the transaction.
-
Catalent Acquires MaSTherCell Global from Great Point Partners and Co-investors
February 3, 2020
Biotechnology
Catalent Pharma Solutions has signed a definitive agreement to acquire MaSTherCell Global, a cell and gene therapy CDMO that Great Point Partners had invested in alongside Orgenesis and SFPI-FPIM. MaSTherCell, headquartered in Gosselies, Belgium with a U.S. facility in Houston, Texas, expands Catalent's cell and gene therapy development and manufacturing capabilities and adds significant European and U.S. capacity.
-
AbCellera Acquires TetraGenetics
September 13, 2021
Biotechnology
AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.
-
Sapiens Acquires Delphi Technology
July 27, 2020
Software
Sapiens International Corporation agreed to acquire Delphi Technology, a Boston-based provider of property & casualty software focused on the medical professional liability (MPL) market. The transaction (up to $19.5 million in cash) is intended to expand Sapiens' North American presence and MPL capabilities by combining Delphi's domain expertise, products and customer base with Sapiens' broader insurance software suite.
-
Lonza AG Acquires PharmaCell BV
June 1, 2017
Biotechnology
Lonza AG has completed the acquisition of PharmaCell BV, a leading European contract manufacturer of cell and gene therapies with facilities in Maastricht and Sittard-Geleen. The deal expands Lonza's autologous cell-therapy manufacturing capabilities in Europe and integrates PharmaCell's GMP production capacity and experienced team into Lonza's global CDMO network.
-
Solvias Acquires Cergentis
July 13, 2022
Biotechnology
Swiss analytical contract research and manufacturing company Solvias acquired Utrecht-based genomics services provider Cergentis on July 12, 2022. The deal adds Cergentis' proprietary Targeted Locus Amplification (TLA) genomic analysis capabilities to Solvias' biologics and cell & gene therapy testing platform to expand its advanced-therapy testing services globally.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.